Keyword: Aurobindo Pharma
China fines vaccine scandal-hit Changsheng $1.3 billion; Merck and Samsung bail on a Lantus biosim; Taiho grows VC fund to sixfold.
Investors might see the deal as "a proxy for what the commodity portions of Teva’s U.S. and Mylan’s U.S. businesses might be worth," says an analyst.
Aurobindo buys parts of Sandoz for $1B; an ex-GSK scientist admits to stealing trade secrets; Lilly and Chi-Med's Chinese-made drug makes history.
The deal relieves Novartis of a troubled franchise while boosting buyer Aurobindo to the second-largest generics player by prescriptions in the U.S.
Takeda plans major cuts after $62 billion Shire buyout; Ascletis files for HK IPO under new listing rules; AZ hands Seroquel rights to Luye Pharma.
India's Aurobindo has submitted a $1.6 billion offer for Novartis' generic dermatology assets in the U.S., according to Livemint.
Merck gets half of Lenvima's sales in $5.8 billion deal; Juno and WuXi's CAR-T JV got $90 million; FDA approved Taiwanese firm's HIV drug.
Regulatory problems are piling up for the sterile manufacturing operations of India’s Aurobindo, which has had another plant cited by the FDA.
Sanofi, aiming to sharpen its focus by offloading its EU generics, is reportedly drawing shoppers from across the globe. The deal could be worth $2B.
Japan’s JSR bought Crown Biosciences, Aurobindo and Dr. Reddy’s responded to Orchid Pharma report, Tessa raised $80 million.